Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.
Myriad Genetics to Grow with Study Successes, New Alliances
by Zacks Equity Research
On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).
Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) moved big last session, as its shares rose over 5% on the day.
Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.
Why Is Myriad Genetics (MYGN) Down 9.6% Since the Last Earnings Report?
by Zacks Equity Research
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics Gets Extended Coverage for Prolaris Test
by Zacks Equity Research
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.
Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 27 cents in the third quarter of fiscal 2017, down 34% year over year.
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.
Myriad Genetics (MYGN) Launches EndoPredict Test in the US
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.
Why Is Myriad Genetics (MYGN) Up 15.8% Since the Last Earnings Report?
by Zacks Equity Research
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag
by Zacks Equity Research
On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).
Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.
Implied Volatility Surging for Myriad Genetics (MYGN) Stock Options
by Zacks Equity Research
Investors in shares of Myriad Genetics, Inc. (MYGN) need to pay close attention to the stock based on moves in the options market lately.
Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Myriad Genetics, Inc.(MYGN) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.
Myriad Genetics: Evidence Street Reviews EndoPredict Test
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.
Myriad Genetics' Unit Releases Favorable Data on Vectra DA
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).
Myriad Genetics: United Rheumatology Selects Vectra DA Test
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.
Will Endopredict Win Myriad's (MYGN) Genomic Testing War?
by Zacks Equity Research
Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.